On Monday, Barclays (LON:BARC) maintained its Overweight rating on Medtronic , Inc. (NYSE:NYSE:MDT) and increased its price target to $109 from the previous $105. The firm expects Medtronic to experience accelerating earnings per share (EPS) growth in the second half of fiscal year 2025, citing solid mid-single-digit (MSD) sales growth and the unwinding of multi-year foreign exchange (FX) hedge expenses as key drivers.
The analyst at Barclays highlighted that the recent sell-off following Medtronic's second-quarter financial results was considered unwarranted. The firm's updated sales and EPS estimates reflect a positive outlook for the medical device company's performance in the forthcoming periods.
Medtronic has been focused on delivering innovative medical technologies, services, and solutions globally. The company's commitment to improving healthcare outcomes is expected to contribute to its financial growth and support the bullish stance from Barclays.
The upgrade in the price target comes as a sign of confidence in Medtronic's potential for revenue and profit growth. The analyst's remarks underscore a belief in the company's ability to navigate market challenges and capitalize on growth opportunities.
Investors and market watchers may see the revised price target and sustained Overweight rating as an indicator of Medtronic's robust business model and its prospects for continued financial success in the evolving healthcare landscape.
In other recent news, Medtronic has received FDA clearance for its innovative Smart MDI system, which includes the InPen™ app and the Simplera™ continuous glucose monitor. The system is designed to aid in diabetes management by providing personalized insulin dosing recommendations. This development is part of Medtronic's ongoing efforts to utilize advanced technology in the field of diabetes management.
Furthermore, the company has reported surpassing second-quarter expectations with revenues of $8.40 billion and earnings per share of $1.26. This positive financial performance led Medtronic to raise its full-year 2025 revenue and EPS guidance. However, Baird lowered Medtronic's price target from $96.00 to $93.00 due to growth concerns, while maintaining a Neutral rating. In contrast, UBS raised its price target for Medtronic to $93.00, citing the company's consistent mid-single-digit revenue growth.
On the analyst front, RBC Capital Markets upgraded Medtronic's rating from Sector Perform to Outperform. However, Goldman Sachs maintained a Sell rating.
InvestingPro Insights
Adding to Barclays' optimistic outlook on Medtronic (NYSE:MDT), recent data from InvestingPro provides further context to the company's financial position and market performance. Medtronic's market capitalization stands at $109.21 billion, reflecting its significant presence in the healthcare equipment sector. The company's P/E ratio of 25.93 suggests that investors are willing to pay a premium for its shares, possibly due to expectations of future growth aligning with Barclays' projections.
InvestingPro Tips highlight Medtronic's strong dividend history, having maintained dividend payments for 48 consecutive years and raised them for 10 consecutive years. This consistent dividend policy supports the company's appeal to income-focused investors and aligns with Barclays' positive stance on the stock. Additionally, Medtronic's revenue growth of 3.25% over the last twelve months and a solid gross profit margin of 65.41% underscore the company's financial health and operational efficiency.
It's worth noting that InvestingPro offers 10 additional tips for Medtronic, providing investors with a more comprehensive analysis of the company's prospects and potential challenges. These insights can be particularly valuable in light of Barclays' upgraded price target and the expected acceleration in EPS growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.